AU2006223002A1 - Macromolecules comprising a thioether cross-link - Google Patents

Macromolecules comprising a thioether cross-link Download PDF

Info

Publication number
AU2006223002A1
AU2006223002A1 AU2006223002A AU2006223002A AU2006223002A1 AU 2006223002 A1 AU2006223002 A1 AU 2006223002A1 AU 2006223002 A AU2006223002 A AU 2006223002A AU 2006223002 A AU2006223002 A AU 2006223002A AU 2006223002 A1 AU2006223002 A1 AU 2006223002A1
Authority
AU
Australia
Prior art keywords
antibody
antibodies
composition
link
thioether cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006223002A
Other languages
English (en)
Inventor
Mark Schenerman
Guillermo I. Tous
Ziping Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2006223002A1 publication Critical patent/AU2006223002A1/en
Assigned to MEDIMMUNE, LLC reassignment MEDIMMUNE, LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: MEDIMMUNE, INC.
Priority to AU2012241127A priority Critical patent/AU2012241127A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2006223002A 2005-03-14 2006-03-14 Macromolecules comprising a thioether cross-link Abandoned AU2006223002A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012241127A AU2012241127A1 (en) 2005-03-14 2012-10-15 Macromolecules comprising a thioether cross-link

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66172405P 2005-03-14 2005-03-14
US60/661,724 2005-03-14
US69913805P 2005-07-13 2005-07-13
US60/699,138 2005-07-13
PCT/US2006/009311 WO2006099481A2 (en) 2005-03-14 2006-03-14 Macromolecules comprising a thioether cross-link

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012241127A Division AU2012241127A1 (en) 2005-03-14 2012-10-15 Macromolecules comprising a thioether cross-link

Publications (1)

Publication Number Publication Date
AU2006223002A1 true AU2006223002A1 (en) 2006-09-21

Family

ID=36992404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006223002A Abandoned AU2006223002A1 (en) 2005-03-14 2006-03-14 Macromolecules comprising a thioether cross-link

Country Status (6)

Country Link
US (2) US20090030187A1 (https=)
EP (1) EP1858911A4 (https=)
JP (1) JP2008536815A (https=)
AU (1) AU2006223002A1 (https=)
CA (1) CA2600844A1 (https=)
WO (1) WO2006099481A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
KR20100052545A (ko) * 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
CA2697612A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
JP5615181B2 (ja) 2007-11-27 2014-10-29 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 関節炎の予防及び治療のための組成物及び方法
CN102065895A (zh) * 2008-04-11 2011-05-18 比奥根艾迪克Ma公司 抗-igf-1r抗体和其它化合物的治疗联合
AU2013337346A1 (en) * 2012-11-05 2015-05-14 Medimmune, Llc Method of isolating Synagis in the absence of benzonase
BR112017008383A2 (en) * 2014-10-31 2018-07-31 Medimmune, Llc improved production method
EP3420362B1 (en) * 2016-02-25 2023-03-22 The Binding Site Group Limited Antibodies
GB201603291D0 (en) * 2016-02-25 2016-04-13 Binding Site Group The Ltd Antibodies
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
AU2017345786B2 (en) 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN110035771B (zh) 2016-10-21 2024-03-08 阿迪马布有限责任公司 抗呼吸道合胞病毒抗体及其产生和使用方法
GB201708262D0 (en) 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease
CN108017717B (zh) * 2018-01-24 2019-08-16 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
JP7842564B2 (ja) * 2018-09-21 2026-04-08 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 粘液を透過するのを制限するための合成結合剤
GB202007047D0 (en) 2020-05-13 2020-06-24 Binding Site Group Ltd Mass spectrometry controls
WO2022175728A1 (en) * 2021-02-19 2022-08-25 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5091542A (en) 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
EP0597997B1 (en) * 1991-08-09 1998-05-20 KOLBECK, Winfried Lanthionine bridged peptides
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
KR100699059B1 (ko) * 1999-04-23 2007-03-23 미쯔비시 가가꾸 가부시끼가이샤 항체 및 폴리알킬렌글리콜 결합 리포좀
US20060123504A1 (en) * 2004-12-07 2006-06-08 Avigenics, Inc. Methods of producing polyclonal antibodies
US20060286548A1 (en) * 2005-06-16 2006-12-21 Gregory Liposky Method of making recombinant human antibodies for use in biosensor technology

Also Published As

Publication number Publication date
EP1858911A4 (en) 2009-12-16
US20090030187A1 (en) 2009-01-29
WO2006099481A2 (en) 2006-09-21
JP2008536815A (ja) 2008-09-11
WO2006099481A3 (en) 2007-04-19
US7786273B2 (en) 2010-08-31
EP1858911A2 (en) 2007-11-28
US20060216284A1 (en) 2006-09-28
CA2600844A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
US7786273B2 (en) Macromolecules comprising a thioether cross-link
US20100278929A1 (en) Antibody formulations having optimized aggregation and fragmentation profiles
JP4934426B2 (ja) 抗体のヒト化
US20090297514A1 (en) Humanization of antibodies
EP2484696A1 (en) Antagonistic human light-specific human monoclonal antibodies
US20060228350A1 (en) Framework-shuffling of antibodies
EP3526256A1 (en) Anti-lag-3 antibodies and methods of use thereof
CA2993432A1 (en) Anti-pd-1 antibodies and methods of use thereof
EP3215538A1 (en) Anti-cd39 antibodies and uses thereof
JP2013013425A (ja) 抗体のフレームワーク・シャッフル
AU2015271685A1 (en) Human monoclonal antibodies to ganglioside GD2
JP2020517242A (ja) 抗ＡｐｏＣ３抗体およびその使用方法
AU2012241127A1 (en) Macromolecules comprising a thioether cross-link
AU2012207043A1 (en) Antibody formulations having optimized aggregation and fragment profiles
CN101273061A (zh) 具有优化的聚集和片段化特性的抗体制剂
WO2024073474A2 (en) Anti-pla2g10 antibodies and methods of use

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted